Announced preclinical data demonstrating the bioequivalence of RT-114, a GLP-1/GLP-2 dual agonist (PG-102) delivered orally via the RaniPill® ...

Treatment with semaglutide improved maximum walking distance in patients with type 2 diabetes (T2D) and symptomatic peripheral artery disease (PAD), according to results from the STRIDE trial ...

Semaglutide, a glucagon-like peptide 1 (GLP-1) agonist, significantly improved maximal walking distance in people with ...

While the exact mechanism is unknown, the data suggest a multitude of benefits independent of large weight loss.

GLP-1 drugs have revolutionised the treatment of obesity, but the very reason they are effective is also why it's vital to ...

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions ...

Lexicon Pharmaceuticals’ pursuit of the last word in obesity candidates has attracted Novo Nordisk. | Lexicon Pharmaceuticals ...

A large majority of older Americans feel that health insurance – including Medicare – should cover anti-obesity medications, according to a new University of Michigan study.

In the past year, treatments such as Wegovy, Mounjaro and Zepbound have become household names. But there are many questions ...

SaveHealth explores what the research says about Ozempic's effects on insulin resistance and related conditions.

A new study has found that a once-weekly injection of semaglutide, a medication originally developed for diabetes and weight ...

One popular and affordable supplement that has shown some promise in helping with weight loss is berberine. In fact, some have called the supplement “nature’s Ozempic,” and with a month’s supply ...